Stada And Alvotech Eye Potential EU Ustekinumab Nod This Year
A Frontrunner Filing For A Stelara Biosimilar Has Been Accepted For Review By The EMA
Alvotech and Stada have indicated that they could receive an EMA opinion on their AVT04 Stelara biosimilar as early as the second half of 2023, after the agency confirmed acceptance of their ustekinumab filing.
